Physician profile
John Smith
NPI 1821075938
$4,164.34
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,321 · 2020: $968 · 2021: $724 · 2022: $355 · 2023: $637 · 2024: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.36 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $650.30 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $374.48 | 2019-2020 | |
| Abbvie INC. | $367.77 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Astellas Pharma US INC | $348.34 | 2019-2023 | |
| Abbott Laboratories | $295.48 | 2020-2024 | Freestyle Libre |
| Glaxosmithkline, LLC. | $295.35 | 2019-2021 | |
| Pfizer INC. | $196.96 | 2019-2024 | |
| Amgen INC. | $174.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.26 | 2019-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $155.81 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $144.20 | 2019-2021 | |
| Allergan, INC. | $127.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $118.55 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $116.11 | 2019-2020 | |
| Lilly USA, LLC | $114.72 | 2019-2023 | Mounjaro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $96.87 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $53.59 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.96 | 2019-2023 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.68 | 2022 | |
| Esperion Therapeutics, INC. | $38.17 | 2021 | |
| Tris Pharma INC | $32.76 | 2023 | Dyanavel Xr |
| Shire North American Group INC | $27.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.35 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.99 | 2019-2021 | |
| Insulet Corporation | $18.77 | 2021 | |
| Agios Pharmaceuticals, INC. | $17.83 | 2024 | |
| Nestle Healthcare Nutrition INC. | $16.66 | 2022 | |
| Exact Sciences Corporation | $15.98 | 2023 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $14.10 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.15 | 2019 | |
| Merck Sharp & Dohme LLC | $12.68 | 2022 | |
| Nevro Corp. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.